On Oct. 29, 2021, Novavax announced the completion of its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its COVID-19 vaccine candidate. The company’s application to the TGA marked the first complete application for provisional approval of a protein-based COVID-19 vaccine in Australia.